Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RAIN
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
- NCT03805841 ↗
- Terminated
- Rain Oncology Inc
- Focused
We haven't built an HCP commentary report on RAIN (tarloxotinib) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RAIN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 6 | |
| YouTube | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- NSCLC, Stage IV; NSCLC Stage IIIB; NSCLC, Stage IIIC; NSCLC, Recurrent; EGFR Exon 20 Insertion Mutation; HER2-activating Mutation; ERBB Fusion; NRG1 Fusion
- Interventions
- tarloxotinib bromide
- Arms
- Active · Experimental
- Enrollment
- 41
- Primary outcomes
- ORR
- Sponsor
- Rain Oncology Inc
- Start
- Mar 13, 2019
- Primary completion
- Apr 9, 2021
- Results posted
- Yes
- Registry record
- NCT03805841 · updated Jun 28, 2023
Publications
linked from the registry- Ye L, Chen X, Zhou F. EGFR-mutant NSCLC: emerging novel drugs. Curr Opin Oncol. 2021 Jan;33(1):87-94. doi: 10.1097/CCO.0000000000000701. PubMed 33122578